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Abstract: Unprecedented investments in health systems in low- and
middle-income countries (LMICs) have resulted in more than 8
million individuals on antiretroviral therapy. Such individuals expe-
rience dramatically increased survival but are increasingly at risk of
developing common noncommunicable diseases (NCDs). Integrating
clinical care for HIV, other infectious diseases, and NCDs could make
health services more effective and provide greater value. Cost-
effectiveness analysis is a method to evaluate the clinical benefits
and costs associated with different health care interventions and offers
guidance for prioritization of investments and scale-up, especially as
resources are increasingly constrained. We first examine tuberculosis
and HIV as 1 example of integrated care already successfully
implemented in several LMICs; we then review the published
literature regarding cervical cancer and depression as 2 examples of
NCDs for which integrating care with HIV services could offer
excellent value. Direct evidence of the benefits of integrated services
generally remains scarce; however, data suggest that improved
effectiveness and reduced costs may be attained by integrating
additional services with existing HIV clinical care. Further investiga-
tion into clinical outcomes and costs of care for NCDs among people
living with HIV in LMICs will help to prioritize specific health care
services by contributing to an understanding of the affordability and
implementation of an integrated approach.
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INTRODUCTION
The number of people living with HIV (PLHIV) with
access to effective and life-saving antiretroviral therapy
(ART) has grown rapidly in low- and middle-income
countries (LMICs) over the past decade.1 Life expectancy
has increased,2–8 and the burden of opportunistic infections
has decreased.9–12 Data from the United States and Europe
demonstrate the increasing burden of noncommunicable dis-
eases (NCDs) among PLHIV in the era of ART.13,14 A similar
trend is anticipated in LMICs,11 where NCDs are already on
the rise among the general population (see Table A1, Sup-
plemental Appendix, http://links.lww.com/QAI/A545),15,16
with earlier age of onset and higher mortality compared with
higher-income countries.17,18 PLHIV in LMICs thus represent
a population in whom preventive, screening, and therapeutic
strategies for NCDs could offer substantial health benefits.19–21
Existing HIV infrastructure offers an opportunity to
address NCDs and their risk factors.2,22–24 To date, integration
strategies have focused primarily on tuberculosis (TB), sexually
transmitted infections, malaria prevention, and reproductive
health,25–28 with some accompanying evaluations of cost-effec-
tiveness.29 To determine the potential value of integrating clin-
ical care for HIV and NCDs, it is critical to first assess the
effectiveness of such integrated interventions. Additional ques-
tions then follow: Is the integrated approach cost-effective com-
pared with the current nonintegrated care? Is it affordable? How
can it best be implemented in a specific setting? Health eco-
nomics offers useful methodologies to answer these questions
and prioritize efforts. Here, we provide an overview of these
methodologies and the data needed for such analyses.
Search Strategy and Selection Criteria
We searched the databases of PubMed and Ovid
for studies published in English before January 30, 2014.
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We used the search terms: “HIV,” “tuberculosis,” and
“noncommunicable diseases” as the first set of terms, with
“cost-effectiveness,” “costs,” “integration,” and “Africa” in
subsequent searches. We also searched for specific NCDs
such as “cervical cancer,” “depression,” and “hypertension.”
We then used the bibliographies of relevant articles to expand
the list of eligible articles.
COST-EFFECTIVENESS ANALYSIS
Cost-effectiveness analysis (CEA) and mathematical
modeling provide guidance for strategic prioritization of
resources by projecting clinical outcomes from specific
strategies and examining the comparative value of different
strategies. CEA evaluates both effectiveness (eg, in years of life
saved) and costs to calculate an incremental cost-effectiveness
ratio (ICER; or Δ costs/Δ effectiveness) that quantifies the
value of different strategies of care. Guided by recommenda-
tions fromWorld Health Organization CHOosing Interventions
that are Cost-Effective (WHO-CHOICE),30 a strategy is often
considered “cost-effective” if its ICER is less than 3 times the
country-specific per capita gross domestic product and “very
cost-effective” if its ICER is less than the per capita gross
domestic product. Such analyses can inform policy and allo-
cation of resources for HIV guidelines and care.31–33
Data Needed
For which specific NCDs will integration with HIV
services have the greatest impact? As discussed by Petersen
et al34 in this supplement, leveraging multi-regional research
and programmatic HIV cohorts in LMICs can identify the
prevalence and incidence of specific NCDs, including their risk
factors and attributable mortality.35–37 The competing risks of
different NCDs and HIV infection must be understood to pri-
oritize an expansion of care services for PLHIV.38,39
The value of integration depends on the accuracy and
availability of screening and prevention strategies, successful
linkage to treatment for those who are eligible, and the
effectiveness of the treatment. Necessary data include diag-
nostic test performance (eg, sensitivity, specificity) in settings
with different disease prevalence (eg, yielding different
positive and negative predictive values), and the risks associ-
ated with screening methods.40 Easily administered, low-cost
tests that yield results rapidly—particularly point-of-care diag-
nostic tests—could be used in integrating NCD screening into
HIV care.41 Access to treatment and risk factor modification
after screening and diagnosis will also affect the value of inte-
grating services.40 Treatment outcomes include effectiveness,
relapse, the frequency and severity of treatment-associated
adverse events, and quality of life,42 using either quality-
adjusted life years43 or disability-adjusted life years.44
Costs are a major consideration, especially where
resources are most limited,45 and include direct medical costs
(eg, diagnostic tests, preventive strategies, treatments) and
costs for infrastructure, personnel, training, and monitoring
and evaluation activities.46,47 Adding costs of NCD screening
and treatment to already overstretched health services must be
weighed against the burden inflicted by NCDs, including the
direct costs associated with management of advanced disease
and indirect costs such as time costs (eg, lost wages) for those
affected.48 Additionally, integrating NCD services with exist-
ing HIV infrastructure could decrease overall costs by taking
advantage of efficiencies of scope.
Outcomes of Interest
CEA can use modeling methods to project clinical
outcomes and comparative value of interventions for NCD
prevention, screening, and management. Although clinical
trials largely define outcomes at early time points, models can
estimate the clinical impact of interventions in the short and
long term. CEA also quantifies the value of one strategy
compared with another by projecting the additional clinical
benefits attained for resources used.
A related methodology, budget impact analysis (BIA),
assesses the costs of a program in specific settings. BIA
focuses on program affordability from the perspective of
stakeholders, such as ministries of health, nongovernmental
organizations, or other payers. These analyses also account
for the direct per capita costs of a program and the number of
patients treated in a given program over a specified budget
period.48 Thus, although a strategy may be cost-effective
when measured against an external threshold of willingness
to pay,30,40,49 BIA assesses the actual resources needed to
implement that strategy in a specific setting.
CASE STUDIES
Integrating clinical services offers an opportunity to
improve overall health among PLHIV but also has the
potential to undermine HIV care. Further investigation will
determine whether outcomes will improve or suffer. After
a systematic review of the literature, we describe TB/HIV as 1
example of existing integrated services and describe data
needed to assess its cost-effectiveness. We then examine
cervical cancer and depression as 2 case examples of the
potential for integrated NCD/HIV care.
TB/HIV Integrated Services
TB: Epidemiology, Quality of Life, and Mortality
TB in PLHIV offers a prime opportunity to assess the
impact and cost-effectiveness of an integrated approach to care
compared with distinct treatment sites. Approximately 1.1
million of the 33.3 million PLHIV in the world were diagnosed
with active TB in 2012 alone.50 PLHIV who have TB experi-
ence a substantially decreased quality of life51 and increased
stigma,52 both of which improve with treatment.53 TB remains
the leading cause of death among PLHIV; almost 25% of those
with HIV and TB worldwide will die from TB.54
TB/HIV: Screening and Treatment Outcomes
Early detection and treatment of TB are critical to
reducing TB mortality and transmission among PLHIV.55–58
Active TB screening results in timely, accurate TB diagnoses
for which effective treatment exists.59–63 However, separate
clinical sites for TB and HIV can result in reduced TB or HIV
Hyle et al J Acquir Immune Defic Syndr  Volume 67, Supplement 1, September 1, 2014
S88 | www.jaids.com  2014 Lippincott Williams & Wilkins
case finding and poor (62%) or delayed (32%) linkage to
care,64 and low rates of ART initiation (13%–62%).64–67
Integration of TB/HIV services can address these short-
comings.68–71 In Guatemala, TB/HIV integration improved ini-
tiation of TB treatment (23% vs. 94%, pre- vs. post-integration)
and decreased mortality at 50 weeks (72% vs. 27%).70 In
Uganda, integration resulted in modest gains; more patients
completed TB treatment (62% vs. 68%, pre- vs. post-) and
fewer experienced death or treatment default (33% vs. 25%).71
Integrated TB/HIV care could lead to improvements
not only in TB but also in HIV outcomes.72 In the Demo-
cratic Republic of Congo, 46% of TB patients preferred HIV
counseling/testing by TB nurses rather than referral to a free-
standing HIV voluntary counseling/testing site (25%) or
a separate, on-site clinic (29%).73 In a Ugandan study,
patients were more likely to initiate ART at some point
during TB treatment (78% vs. 94%), especially during the
earlier intensive treatment phase (23% vs. 60%).71 In an
integrated South African site, time to ART initiation
decreased from 147 days to 75 days, and patients were
1.6 times more likely to start ART.74
TB/HIV: Costs
Although the direct costs of TB and HIV care have
been reported,75,76 the detailed costs and tradeoffs of inte-
grated TB/HIV care are not yet well described. In addition
to diagnostic tests and medications, costs include infrastruc-
ture, personnel, and training.77 Integrated TB/HIV care could
reduce overall resource utilization by relying on efficiencies
of scope to increase the value of existing infrastructure
and personnel.
Cost-effectiveness of TB/HIV Integration
Several studies have examined the cost-effectiveness of
specific aspects of integrated TB/HIV care. Integrating
routine HIV testing into TB treatment clinics in India is “very
cost-effective” when compared with selective screening78 and
is likely to be even more cost-effective in settings with higher
HIV prevalence because more people are likely to be diag-
nosed with HIV and linked to care.59,79,80 Integrating TB
screening methods (eg, Xpert MTB/RIF or urine LAM) when
initiating ART for PLHIV can be cost-effective in South
Africa as compared with symptom screening and sputum
smear or sputum culture.81–83 Point-of-care tests that improve
linkage to care could outweigh limitations in test character-
istics, such as reduced sensitivity or specificity, when com-
pared with a laboratory-based test.84 Isoniazid preventive
therapy among PLHIV offers another example of how inte-
grating an aspect of TB prevention into HIV services can be
cost-effective.80,85–87
OPPORTUNITIES TO INTEGRATE HIV
AND NCD CARE: USING A
COST-EFFECTIVENESS APPROACH
In terms of value, data are limited but promising
regarding the impact on NCD outcomes of integrating HIV
care into primary care.22,88,89 Screening for NCDs and their risk
factors, as well as associated treatments, fall along a wide spec-
trum regarding continuity of care and costs (see Table A3,
Supplemental Appendix, http://links.lww.com/QAI/A545).
Interventions are more costly if they require intensive training
or the use of new technologies or if they occur at frequent
intervals among large numbers of people. Cervical cancer and
depression are 2 examples of NCDs that merit further evalua-
tion regarding the potential value of integration.
CERVICAL CANCER/HIV INTEGRATED SERVICES
Cervical Cancer: Epidemiology
As further described by Adebamowo et al in this
supplement,90 invasive cervical cancer (ICC) will likely be
a major cause of mortality as women living with HIV gain
increased access to ART in sub-Saharan Africa (SSA).91,92
The incidence of ICC in SSA is the highest in the world;
age-standardized incidence rates in the general population
range from 28 to 42.7 cases per 100,000 women.91 HIV-in-
fected women are at even greater risk for ICC,93–96 which often
occurs at younger ages97 and presents at more advanced stages
when treatment is less likely to be successful.98 Furthermore,
ART may not reduce cervical cancer risk, and life-long screen-
ing is needed.98,99
Cervical Cancer: Screening and
Treatment Outcomes
ICC often manifests with precursor cervical lesions evident
with screening and amenable to treatment. Multiple screening
methods have demonstrated accuracy in LMICs,91,100 with the
ability to incorporate mobile technologies101,102 and well-trained
nonphysician clinicians to extend services.97,102,103 Likewise,
when precancerous lesions are identified, multiple treatment
options demonstrate excellent efficacy in LMICs.102,104–108 Oper-
ational aspects of screening and treatment for ICC and its
precursor lesions have been demonstrated in Zambia, with
more than 65,000 women screened in the first 5 years of a large
program109,110 and more than 110,000 women screened over the
past 8 years.111
Although screening is available and accurate, only
0.4%–20.2% of African women receive even 1 screening test
in their lifetimes.91,102,112,113 Loss to follow-up after initial diag-
nosis is high, and treatment opportunities are missed.97,114 Inte-
grating ICC screening and treatment with HIV services could
offer improved uptake of screening and treatment outcomes.
Cervical Cancer: Costs
Studies have reported on the costs of reagents, tech-
nologies, and infrastructure for cervical cancer screening
programs in LMICs, including cytology ($2.0–4.4 per speci-
men), human papillomavirus DNA testing ($7.9–8.6 per test),
and visual inspection with acetic acid (,$5 per test).115,116
Costs for staff, training, and quality assurance of procedures
have not been reported, and the efficiencies of scope attained
with integration of services have not yet been established.
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Cost-effectiveness of Cervical Cancer and
HIV Integration
Although extensive literature exists on the cost-
effectiveness of screening interventions to reduce ICC among
the general population in LMICs117–121 and among PLHIV in
high-income settings,122 cost-effectiveness literature is limited
regarding ICC in PLHIV in LMICs. A study from Brazil
suggests that a 2-tiered screening approach (ie, annual human
papillomavirus screening followed by cytology, if positive) is
very cost-effective in HIV-infected women123; integrating
such an approach into routine HIV care could further increase
its value if outcomes are maintained and uptake improved. An
analysis in SSA suggests that only 262 HIV-infected women
receiving ART would need to be screened to prevent 1 cer-
vical cancer death.124 Integration with HIV services and the
utilization of existing infrastructure have the potential to facil-
itate scale-up and decrease barriers to access.114,125
DEPRESSION/HIV INTEGRATED SERVICES
Depression: Epidemiology and Quality of Life
Depression is highly prevalent among PLHIV in SSA,
requiring repeated screening and longitudinal treatment, as
described by Chibanda et al126 in this supplement. Up to 40%
of PLHIV attending ART clinics in LMICs suffer from
depression,127–134 and specific subgroups, such as women,
are at particularly high risk.135–138
Depression can negatively impact adherence to ART,
leading to worse HIV outcomes.130–132,139–143 In a meta-analysis
from SSA, ART adherence was 55% lower in patients with
depression symptoms.134 Women with HIV who reported
symptoms of depression also experienced accelerated HIV dis-
ease progression and higher mortality.138 Depression among
PLHIV has been correlated with reduced quality of life in the
United States,144 and early evidence suggests the same in SSA.145
Depression: Screening and
Treatment Outcomes
Simple screening strategies for depression are feasible
in LMICs and in HIV-infected populations, offering an
opportunity for integration.146,147 Short surveys have been
validated in HIV-uninfected populations,148 as have longer
surveys149 and visual scales.150 Incorporating screening for
substance use, especially alcohol use, could offer particular
benefit, given its comorbidity with both HIV and depres-
sion.151,152 Integration of depression screening with HIV care
could improve case detection and management.153
Treatment options for depression exist in LMICs. Medi-
cations, cognitive behavioral therapy, and interpersonal therapy
have all been studied in PLHIV in LMICs.147,154–156 Further study
is needed on the accessibility and sustainability of these inter-
ventions, the quantification of their impact on quality of life and
life expectancy, and their integration into routine HIV care.139
Depression: Costs
Costs of screening for and treating depression include
personnel, training, therapy, and associated medications,
which could offset other medical costs from utilization of
health services and improve economic outcomes in treated
patients.157–159 If successful diagnosis and treatment of
depression increased ART adherence or retention in care, then
costly second-line ART regimens could be deferred or
avoided. However, the scale of such benefit is unclear.
Cost-effectiveness of Depression/HIV
Integration
In high-income country general populations, CEA has
demonstrated that integrating depression screening and
treatment with primary care can be cost-effective.157,158
Decreased overall costs of care can be achieved by integrating
care for HIV, mental health, and substance use in the United
States; longer follow-up for such interventions will provide
more data about the sustainability of such an approach.159
This question, to our knowledge, has not yet been studied
in LMICs.
TRADEOFFS AND CHALLENGES ASSOCIATED
WITH IMPLEMENTATION OF
INTEGRATED SERVICES
The optimal implementation of integrated strategies in
specific settings remains to be determined,160 and integrated
care could have unintended consequences. Wait times
increased from 91 to 127 minutes in a Zambian clinic because
of staff and patient flow problems after integration of HIV
services with primary health care.161 Longer wait times could
increase loss to follow-up or exacerbate stigma,162–164 and TB
transmissions could even be increased.69,165 Staff training and
program quality might be less effective or more costly when
multiple interventions are provided together.166 Developing
quality indicators for NCD and HIV outcomes will assist in
programmatic feedback and assessment of these potential
tradeoffs.166–169
The benefits of introducing integrated services and new
technologies can be realized only if accompanied by initia-
tives that strengthen health systems, as emphasized by the
Gene Xpert experience in South Africa.170–172 Any value of
integrating NCDs or TB with HIV clinical care will only be
achieved if health systems are capable of providing high-
quality clinical care consistently and rapidly.
Integration of NCD/HIV services could build on
innovative approaches from a diversity of tools and experi-
ences. The expanded use of mobile health (mHealth) suggests
that information technologies can improve effectiveness and
decrease costs for integrated care.101,173,174 Analyses of pri-
mary health clinics in LMICs, which face similar challenges
in terms of a management of diverse comorbidities, can offer
guidance regarding NCD care for PLHIV.175 NCD screening
and treatment could be included in decentralized public health
clinics, mobile clinics, community-based campaigns, or
home-based care, which may offer additional opportunities
for accessing those absent from clinics and allow for
increased coverage by integrated services.176–180 Although
integration and expansion of NCD care within HIV services
can be implemented more easily in settings with more
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established health care infrastructures,181 integration may
offer even more clinical benefits in the most resource-
limited settings where NCD services are not yet routinely
available. Barriers to access and methods to facilitate scale-
up need investigation in specific clinical settings.
RESEARCH AND TRAINING AGENDAS
To assess the value of different strategies for screening,
prevention, and management of NCDs among PLHIV in
LMICs, innovative research at the intersection of NCDs and
HIV in LMICs is warranted (Table 1). Data needed include
the incidence and prevalence of various NCDs among PLHIV
in LMICs, screening and treatment outcomes, effects of
NCDs on quality of life in PLHIV, and the costs associated
with managing these comorbidities. The specific assessment
of integrated services and the implementation of best practi-
ces are also critical.
Clinical training of health care workers for NCD
screening and treatment is necessary,167,182 as is further train-
ing of students and health professionals in epidemiology and
implementation science.183 As new programmatic initiatives
are developed for NCDs in LMICs, formal training in costing
methodology, CEA, and BIA will offer opportunities for
capacity building to assist policymakers at local, regional,
and national levels.
SUMMARY AND CONCLUSIONS
The remarkable success of ART scale-up in LMICs has
established an infrastructure for providing longitudinal
medical care to millions of people. PLHIV are living longer
and healthier lives but are now at risk for morbidity and
mortality from NCDs. The clinical impact and costs of
different strategies for NCD prevention, management, and
diagnosis in PLHIV is beginning to be quantified. Imple-
mentation science can inform the adaptation and expansion of
lessons learned from HIV and TB/HIV integrated care to
NCDs. Optimal strategies will vary by country, setting, and
the underlying burden of different NCDs. Cost-effectiveness
and BIA, in addition to observational studies and randomized
clinical trials, are complementary tools to assess the value of
screening for and treatment of NCDs and can inform health
policy in an era marked by very effective HIV therapy,
a growing NCD burden, and increasingly limited resources.
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